Lewis Clayton Jr. Cantley Sells 3,838 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,838 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the transaction, the director now owns 80,851 shares in the company, valued at $4,800,123.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, November 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $60.88, for a total transaction of $243,520.00.
  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.09, for a total transaction of $71,090.00.
  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total transaction of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.59, for a total transaction of $262,360.00.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up $0.14 during mid-day trading on Friday, hitting $60.97. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period in the prior year, the business earned ($1.63) earnings per share. Agios Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current year.

A number of equities analysts have commented on AGIO shares. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 17th. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $75.70.

Several hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC raised its stake in shares of Agios Pharmaceuticals by 2.3% during the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock worth $1,767,000 after buying an additional 666 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth approximately $206,000. Public Employees Retirement Association of Colorado raised its stake in shares of Agios Pharmaceuticals by 5.2% during the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 323 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Agios Pharmaceuticals by 9.7% during the second quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 425 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of Agios Pharmaceuticals by 84.6% during the second quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 2,541 shares during the last quarter. Institutional investors own 94.38% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/12/10/lewis-clayton-jr-cantley-sells-3838-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply